Development of newer calcium channel antagonists: Therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation

Drugs

Volumn 69, Issue 1, 2009, Pages 21-30

  Ohashi, Narutaka ^a   Mitamura, Hideo ^b   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DILTIAZEM; EFONIDIPINE; ENALAPRIL; MIBEFRADIL; NIFEDIPINE; VERAPAMIL;

CLINICAL TRIAL; DOG; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ELECTRICAL REMODELLING; EXPERIMENTAL STUDY; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE POTENTIAL; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORNING DOSAGE; NONHUMAN; PACEMAKER; PULMONARY VEIN; RENAL PROTECTION; REVIEW; SINUS NODE; SYMPATHETIC TONE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; DIHYDROPYRIDINES; DRUG DELIVERY SYSTEMS; HUMANS; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS;

CANIS FAMILIARIS;

EID: 59749083760     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969010-00002     Document Type: Review

References (73)

1. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989 Nov 11; 299 (6709): 1187-92
2. Ishikawa K, Nakai S, Takenaka T, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997 May 20; 95 (10): 2368-73
3. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997 Dec 1; 80 (11): 1453-8
4. Staessen JA, Fagard R, Thijs L, et al. Randomized doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997 Sep 13; 350 (9080): 757-64
5. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004 Sep 4; 364 (9437): 849-57
6. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10-16; 366 (9489): 895-906
7. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004 Nov 10; 292 (18): 2217-25
8. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003 Jan; 83 (1): 117-61
9. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII: nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005 Dec; 57 (4): 397-409
10. 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988 Jan 1; 239 (4835): 57-61
11. 2+ channels by amlodipine. Br J Pharmacol 1997 Jul; 121 (6): 1136-40
12. Donati L, Buhler FR, Beretta-Piccoli C, et al. Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. Clin Pharmacol Ther 1992 Jul; 52 (1): 50-9
13. Leenen FH, Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am J Cardiol 1996 Jul 15; 78 (2): 203-7
14. 2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999 Nov; 291 (2): 464-73
15. 2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs. J Pharmacol Sci 2004 Oct; 96 (2): 219-23
16. Hagiwara N, Irisawa H, Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 1988; 395: 233-53
17. 2+ release contributes to automaticity in cat atrial pacemaker cells. J Physiol 2000 Apr 15; 524 (Pt 2): 415-22
18. 2+ channels in cardiac pacemaking. J Pharmacol Sci 2005 Nov; 99 (3): 197-204
19. Mangoni ME, Traboulsie A, Leoni AL, et al. Bradycardia and slowing of the atrioventricular conduction in mice lacking CaV3.1/alpha1G T-type calcium channels. Circ Res 2006 Jun 9; 98 (11): 1422-30
20. 2+ channels. Science 2003 Nov 21; 302 (5649): 1416-8
21. 2+) channels. Neuron 2001 Jul 19; 31 (1): 35-45
22. 2+ channels. Science 2003 Oct 3; 302 (5642): 117-9
23. Vitko I, Chen Y, Arias JM, et al. Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel. J Neurosci 2005 May 11; 25 (19): 4844-55
24. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation 2000 Feb 22; 101 (7): 758-64
25. Gläser S, Steinbach M, Opitz C, et al. Torsades de pointes caused by mibefradil. Eur J Heart Fail 2001 Oct; 3 (5): 627-30
26. Masuda Y, Tanaka S. Efonidipine hydrochloride: a new calcium antagonist. Cardiovasc Drug Rev 1994; 12 (2): 123-35
27. Yamada K, Ishii M, Mizuno Y, et al. Clinical evaluation of the antihypertensive effect of NZ-105 in patients with essential hypertension [in Japanese]. J Clin Exp Med 1992; 161: 275-92
28. Shinozaki Y, Himori Y, Sano H, et al. Studies on the metabolic fate of NZ-105: absorption, distribution, metabolism and excretion after a single administration to rats. Xenobio Metabol and Dispors 1991; 6: 919-32
29. Yamashita T, Masuda Y, Sakai T, et al. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta. Jpn J Pharmacol 1991 Nov; 57 (3): 337-48
30. 2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol 1998 May 22; 349 (2-3): 351-7
31. 2+ current by efonidipine in cardiomyocytes. Life Sci 2000 Dec 8; 68 (3): 345-51
32. Lee TS, Kaku T, Takebayashi S, et al. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology 2006; 78 (1): 11-20
33. 2+ channels. Br J Pharmacol 2004 Dec; 143 (8): 1050-7
34. Tanaka H, Komikado C, Shimada H, et al. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J Pharmacol Sci 2004 Dec; 96 (4): 499-501
35. Sugano N, Wakino S, Kanda T, et al. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008 Apr; 73 (7): 826-34
36. JATOS Study Group. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 2005 Jun; 28 (6): 513-20
37. Oshima T, Ozono R, Yano Y, et al. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 2005 Nov; 28 (11): 889-94
38. Andreasen D, Jensen BL, Hansen PB, et al. The alpha(1G)-subunit of a voltage-dependent Ca(2+) channel is localized in rat distal nephron and collecting duct. Am J Physiol Renal Physiol 2000 Dec; 279 (6): F997-1005
39. Hansen PB, Jensen BL, Andreasen D, et al. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001 Sep 28; 89 (7): 630-8
40. Hayashi K, Nagahama T, Oka K, et al. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996 Mar 1; 19 (1): 31-6
41. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007 Feb 16; 100 (3): 342-53
42. Fujiwara K, Kanno Y, Hayashi K, et al. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998 Apr; 20 (3): 295-312
43. Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003 Feb; 16 (2): 116-22
44. Hayashi K, Ozawa Y, Fujiwara K, et al. Role of actions of calcium antagonists on efferent arterioles: with special references to glomerular hypertension. Am J Nephrol 2003 Jul-Aug; 23 (4): 229-44
45. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994 Jul; 75 (1): 149-55
46. 2+) channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 1999 Sep; 31 (9): 1617-25
47. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993 Oct; 73 (4): 777-82
48. Villame J, Massicotte J, Jasmin G, et al. Effects of mibefradil, a T- and L-type calcium channel blocker, on cardiac remodeling in the UM-X7.1 cardiomyopathic hamster. Cardiovasc Drugs Ther 2001 Jan; 15 (1): 41-8
49. Mulder P, Richard V, Compagnon P, et al. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997 Feb; 29 (2): 416-21
50. Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin IIinduced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993 Jul; 92 (1): 398-403
51. Izumi T, Kihara Y, Sarai N, et al. Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro. Circulation 2003 Nov 18; 108 (20): 2530-5
52. Lalevee N, Rebsamen MC, Barrere-Lemaire S, et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005 Aug 1; 67 (2): 216-24
53. Hoglund C, Cifkova R, Mimran A, et al. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. Cardiology 1998 May; 89 (4): 263-70
54. Tzivoni D, Kadr H, Braat S, et al. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation 1997 Oct 21; 96 (8): 2557-64
55. Leuranguer V, Monteil A, Bourinet E, et al. T-type calcium currents in rat cardiomyocytes during postnatal development: contribution to hormone secretion. Am J Physiol Heart Circ Physiol 2000 Nov; 279 (5): H2540-8
56. Gaborit N, Le Bouter S, Szuts V, et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 2007 Jul 15; 582 (Pt 2): 675-93
57. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995 Oct 1; 92 (7): 1954-68
58. Yue L, Melnyk P, Gaspo R, et al. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999 Apr 16; 84 (7): 776-84
59. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997 Oct; 81 (4): 512-25
60. Sun H, Chartier D, Leblanc N, et al. Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001 Mar; 49 (4): 751-61
61. Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997 Apr 1; 95 (7): 1945-53
62. Ramanna H, Elvan A, Wittkampf FH, et al. Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. J Am Coll Cardiol 2001 Apr; 37 (5): 1403-7
63. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000 Jan 18; 101 (2): 200-6
64. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999Nov 23; 100 (21): 2191-7
65. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001 Mar; 49 (4): 762-70
66. Ohashi N, Mitamura H, Tanimoto K, et al. A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling. J Cardiovasc Pharmacol 2004 Sep; 44 (3): 386-92
67. Chen YC, Chen SA, Chen YJ, et al. T-type calcium current in electrical activity of cardiomyocytes isolated from rabbit pulmonary vein. J Cardiovasc Electrophysiol 2004 May; 15 (5): 567-71
68. Yamashita N, Kaku T, Uchino T, et al. Short- and long-term amiodarone treatments regulate Cav3.2 low-voltage-activated T-type Ca2+ channel through distinct mechanisms. Mol Pharmacol 2006 May; 69 (5):1684-91
69. Shinagawa K, Shiroshita-Takeshita A, Schram G, et al. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003 Mar 18; 107 (10): 1440-6
70. Cohen CJ, Spires S, Van Skiver D. Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol 1992 Oct; 100 (4): 703-28
71. Fujiki A, Tsuneda T, Sugao M, et al. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003 Aug 15; 92 (4): 472-5
72. Sato D, Niwano S, Imaki R, et al. Bepridil inhibits subacute phase of atrial electrical remodeling in canine rapid atrial stimulation model. Circ J 2006 Feb; 70 (2): 206-13
73. Uchino T, Lee TS, Kaku T, et al. Voltage-dependent and frequency-independent inhibition of recombinant Cav3.2 T-type Ca2+ channel by bepridil. Pharmacology 2005 Jul; 74 (4): 174-81